Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.
文献类型：期刊论文
| 作者 | Si, Lu; Fang, Meiyu; Chen, Yu ; Mao, Lili; Zhang, Peng; Lin, Jing; Bai, Xue; Cao, Xiao; Chen, Yi; Guo, Jun
|
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2021-05-20 |
| 卷号 | 39 |
| ISSN号 | 0732-183X |
| DOI | 10.1200/JCO.2021.39.15_suppl.9511 |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000708120605115 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126700]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Fujian Canc Hosp, Dept Med Oncol, Fuzhou, Peoples R China 2.Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Dept Rare Canc & Head & Neck Med Oncol, Beijing, Peoples R China 4.Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Hangzhou, Peoples R China 5.Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Renal Canc & Melanoma,Canc Hosp & Inst, Beijing, Peoples R China 6.Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China 7.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Si, Lu,Fang, Meiyu,Chen, Yu,et al. Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
| APA | Si, Lu.,Fang, Meiyu.,Chen, Yu.,Mao, Lili.,Zhang, Peng.,...&Guo, Jun.(2021).Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial..JOURNAL OF CLINICAL ONCOLOGY,39. |
| MLA | Si, Lu,et al."Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。